- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02461004
CKD-391 Pharmacokinetic Study
October 13, 2016 updated by: Chong Kun Dang Pharmaceutical
Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects
A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To compare the CKD-391 (Experimental product) to the dose Atorvastatin calcium and Ezetimibe combination in health male subjects is the purpose of this trial.
Following are evaluated in this trial; Characteristics and safety/Tolerability Of CKD-391.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- The Korea University Anam Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Bwt >=50kg, BMI 18~29
- signed the informed consent form prior to the study participation
Exclusion Criteria:
- Clinically significant disease
- Subject has signs of symptoms of acute disease within 28 days of starting administration of investigational drug
- Clinically significant allergic disease
- Impossible to taking the institutional standard meal
- Previously donate whole blood within 60 days or component blood within 20 days
- Previously participated in other trial within 90 days
- Continued to be taking caffeine (caffeine > 5 cup/day), drinking(alcohol > 30 g/day) or cannot stop drinking or severe heavy smoker(cigarette > 10 cigarettes per day)during clinical trials
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TR group
CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
|
Investigational product is prescribed to all of radomized subjects for two times.
Investigational products are prescribed to all of radomized subjects for two times.
|
Experimental: RT group
combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
|
Investigational product is prescribed to all of radomized subjects for two times.
Investigational products are prescribed to all of radomized subjects for two times.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUClast
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
Cmax
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tmax
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
T1/2
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
AUCinf
Time Frame: up to 96 hours post dose
|
up to 96 hours post dose
|
Adverse events
Time Frame: up to 24days post dose
|
up to 24days post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ji Young Park, Ph.D., The Korea University Anam Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
June 1, 2015
First Submitted That Met QC Criteria
June 2, 2015
First Posted (Estimate)
June 3, 2015
Study Record Updates
Last Update Posted (Estimate)
October 17, 2016
Last Update Submitted That Met QC Criteria
October 13, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 152BE15016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on CKD-391
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalSeoul National University Bundang HospitalCompleted
-
SignalChem Lifesciences CorporationCompleted
-
SignalChem Lifesciences CorporationSyneos HealthCompletedFood-drug InteractionCanada
-
Chong Kun Dang PharmaceuticalCompletedHealthyKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of